ACADIA Pharmaceuticals (ACAD) surges 145.7 percent to $5.65 in premarket after company said its antipsychotic drug for Parkinson's disease succeeded in meeting the primary goal and key secondary goals of a pivotal late stage clinical trial following the success of
its Phase III trial for Pimavanserin. "Home run for them," is Jason Napodano's
quick take after looking over the data. Of particular interest, he says, is the
testing showed no negative impact on motor function, unlike clozapine or
quetiapine.
Technical side stock has resistance $6.60 & $7.30.
Technical side stock has resistance $6.60 & $7.30.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
